My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search
Jubilant Life Sciences advances after getting ANDA approval for Levetiracetam
Jun 06,2016

The announcement was made after market hours on Friday, 3 June 2016.

Meanwhile, the S&P BSE Sensex was down 5.69 points or 0.02% at 26,837.34

On BSE, so far 53,360 shares were traded in the counter as against average daily volume of 1.53 lakh shares in the past one quarter. The stock hit a high of Rs 374 and a low of Rs 366.25 so far during the day. The stock had hit a record high of Rs 455 on 7 December 2015. The stock had hit a 52-week low of Rs 163.35 on 29 June 2015. The stock had underperformed the market over the past one month till 3 June 2016, falling 9.42% compared with Sensexs 6.39% rise. The scrip had also underperformed the market in past one quarter, declining 4.71% as against Sensexs 9.09% rise.

The mid-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.

Jubilant Life Sciences announced that the company has received Abbreviated New Drug Application (ANDA) final approval for Levetiracetam Injection USP, 500 mg/5 mL (100 mg/mL), the generic version of Keppra Injection 500mg/5mL (100mg/mL) of UCB, which is used for the treatment of epilepsy. As on 31 March 2016, Jubilant Life Sciences had a total of 739 filings for formulations of which 517 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 44 have been approved and 46 Dossier filings in Europe.

Jubilant Life Sciences consolidated net profit rose 65.4% to Rs 70.68 crore on 2.8% fall in net sales to Rs 1480.29 crore in Q4 March 2016 over Q4 March 2015.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, solid dosage formulations, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery solutions.

Powered by Capital Market - Live News

Jubilant Life Sciences surges after USFDA nod for a generic drug
Jun 06,2016

The company made the announcement after market hours on Friday, 3 June 2016.

Meanwhile, the S&P BSE Sensex was down 5.69 points or 0.02% at 26,837.34

On BSE, so far 53,360 shares were traded in the counter as against average daily volume of 1.53 lakh shares in the past one quarter. The stock hit a high of Rs 374 and a low of Rs 366.25 so far during the day. The stock had hit a record high of Rs 455 on 7 December 2015. The stock had hit a 52-week low of Rs 163.35 on 29 June 2015. The stock had underperformed the market over the past one month till 3 June 2016, falling 9.42% compared with Sensexs 6.39% rise. The scrip had also underperformed the market in past one quarter, declining 4.71% as against Sensexs 9.09% rise.

The mid-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.

The approval is for the generic version of Keppra Injection 500mg/5mL (100mg/mL) of UCB, which is used for the treatment of epilepsy.

As on 31 March 2016, Jubilant Life Sciences had a total of 739 filings for formulations, of which 517 have been approved in various regions globally. This includes 72 ANDAs (Abbreviated New Drug Application) filed in the US, of which 44 have been approved. It also includes 46 dossier filings in Europe.

Jubilant Life Sciences consolidated net profit rose 65.4% to Rs 70.68 crore on 2.8% fall in net sales to Rs 1480.29 crore in Q4 March 2016 over Q4 March 2015.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of active pharmaceutical ingredients, solid dosage formulations, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery solutions.

Powered by Capital Market - Live News

HDFC turns volatile after acquisition of L&Ts insurance biz
Jun 06,2016

The announcement was made after market hours on Friday, 3 June 2016.

Shares of L&T were up 0.44% at Rs 1,467.50.

Meanwhile, the S&P BSE Sensex was down 20.88 points or 0.08% at 26,822.15.

On BSE, so far 13,000 shares of Housing Development Finance Corporation (HDFC) exchanged hands in the counter compared with average daily volume of 1.78 lakh shares in the past one quarter. The stock was volatile. The stock lost as much as 0.55% at the days low of Rs 1,248 so far during the day. The stock rose as much as 0.79% at the days high of Rs 1,265 so far during the day. The stock had hit a 52-week high of Rs 1,370.80 on 16 July 2015. The stock had hit a 52-week low of Rs 1,012 on 25 February 2016. The stock had outperformed the market over the past one month till 3 June 2016, advancing 14.19% compared with Sensexs 6.39% rise. The scrip had also outperformed the market in past one quarter, gaining 11.74% as against Sensexs 9.09% rise.

The large-cap company has equity capital of Rs 316.08 crore. Face value per share is Rs 2.

HDFC said that the board of directors of HDFC ERGO General Insurance Company (HDFC ERGO), a non listed subsidiary of the company, has approved the acquisition of a 100% stake in L&T General Insurance Company (LTGI) for an aggregate consideration of Rs 551 crore. The board of HDFC ERGO also approved the plan to merge the two companies subject to all regulatory approvals. The acquisition would help HDFC ERGO improve its market position. HDFC ERGO expects significant cost synergies arising out of business, technology optimization and rationalization of offices.

HDFC ERGO, a 51:49 joint venture between housing major HDFC and ERGO International, Germany (part of Munich Re Group), is the 4th largest private sector general insurer in India and offers all lines of general insurance products including motor, health, personal accident, home, fire, marine, aviation, liability, crop insurance etc.

The transaction is subject to various approvals, including approval of Insurance Regulatory and Development Authority of India and the Bombay High Court.

Upon closing, the L&T Group would exit from the general insurance and health insurance business.

LTGI gross earned premium income during the year 2015-2016 was Rs 483 crore, constituting around 0.5% of the companys consolidated revenue for the year 2015-2016 and reported a net worth of Rs 142 crore as on 31 March 2016. The share sale is part of L&Ts strategy of exiting from its non-core activity.

On consolidated basis, HDFCs net profit rose 30.8% to Rs 3460.46 crore on 15.5% growth in total income to Rs 17027.21 crore in Q4 March 2016 over Q4 March 2015.

HDFC is Indias first retail housing finance company and is currently one of the largest originators of housing loans in the country.

Powered by Capital Market - Live News

Cadila Healthcare gains on securing USFDA nod for phase II clinical trial of Saroglitazar
Jun 06,2016

The announcement was made on Saturday, 4 June 2016.

Meanwhile, the BSE Sensex was up 30.43 points, or 0.11%, to 26,873.46

On BSE, so far 14,000 shares were traded in the counter, compared with an average volume of 92,935 shares in the past one quarter. The stock hit a high of Rs 325.35 and a low of Rs 321.05 so far during the day. The stock hit a record high of Rs 454.40 on 23 October 2015. The stock hit a 52-week low of Rs 295.50 on 18 January 2016.

The large-cap company has an equity capital of Rs 102.37 crore. Face value per share is Re 1.

Cadila Healthcare announced on Saturday, 4 June 2016, that the United States Food and Drug Administration (USFDA) approved the companys plan to initiate a phase 2 clinical trial of Saroglitazar in patients with non-alcoholic Steatohepatitis (NASH) of the liver. This randomized, double-blind phase 2 trial will evaluate Saroglitazar 1mg, 2mg and 4mg Vs. Placebo. Commenting on the development, Pankaj Patel, Chairman and Managing Director of Cadila Healthcare said that NASH is an area of unmet healthcare need as there are currently no drugs approved for the treatment of NASH. Saroglitazar has significant and differentiated effect on hepatic steatosis, while it shows all other beneficial effects on reducing inflammation and fibrosis in the liver in NASH models, Patel said. With a phase III trial in biopsy proven NASH patients ongoing in India and a phase II trial in NASH patients planned in USA, Cadila is committed towards developing this drug for millions of patients suffering from NASH, Patel said.

Cadila Healthcares consolidated net profit rose 10.9% to Rs 388.70 crore on 5.7% growth in net sales to Rs 2375.50 crore in Q4 March 2016 over Q4 March 2015.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News

RIL inches up after resumption of operations at Dahej plants
Jun 06,2016

The announcement was made after market hours on Friday, 3 June 2016.

Meanwhile, the S&P BSE Sensex was up 8.20 points or 0.03% at 26,851.23.

On BSE, so far 1,438 shares were traded in the counter as against average daily volume of 2.27 lakh shares in the past two weeks. The stock hit a high of Rs 962 and a low of Rs 959 so far during the day. The stock had hit a 52-week high of Rs 1,089.50 on 15 January 2016. The stock had hit a 52-week low of Rs 819 on 24 August 2015.

The large-cap company has equity capital of Rs 3242.45 crore. Face value per share is Rs 10.

The purified terephthalic acid (PTA) plants had been shut for a brief period owing to increased water salinity. Reliance Industries (RIL) said it ensured PTA supplies to downstream customers from its Hazira and Patalganga plants during the brief shutdown at Dahej. Now, the customers will be getting PTA from all three locations, RIL said.

On consolidated basis, RILs net profit rose 15.9% to Rs 7398 crore on 10.7% decline in net sales to Rs 60252 crore in Q4 March 2016 over Q4 March 2015.

RIL is a diversified firm having presence in oil exploration, petrochemicals, retail and telecom sectors.

Powered by Capital Market - Live News

Natco Pharma jumps as partner gets USFDA tentative approval for Sorafenib Tablets
Jun 03,2016

The announcement was made during market hours today, 3 June 2016.

Meanwhile, the S&P BSE Sensex was down 2.50 points or 0.01% at 26,840.64

On BSE, so far 4.69 lakh shares were traded in the counter as against average daily volume of 59,833 shares in the past one quarter. The stock hit a high of Rs 522.65 and a low of Rs 480 so far during the day. The stock had hit a 52-week low of Rs 382.20 on 24 August 2015. The stock had hit a record high of Rs 623.60 on 5 January 2016. The stock had underperformed the market over the past one month till 2 June 2016, rising 0.07% compared with Sensexs 5.53% gains. The scrip also underperformed the market in past one quarter, rising 8.96% as against Sensexs 10.73% gains.

The mid-cap company has equity capital of Rs 34.83 crore. Face value per share is Rs 2.

Natco Pharma announced today, 3 June 2016 that its marketing partner, Mylan Inc. has received a tentative approval for its Abbreviated New Drug Application (ANDA) for Sorafenib Tablets, 200mg, with the US Food and Drug Administration (USFDA). This product is the generic version of NEXAVAR, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Natco Pharma and Mylan have filed an ANDA containing a Paragraph IV certification for this product. Natco Pharma manufactures this product at its facility in Kothur, Telangana.

Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., sells Sorafenib Tablets, 200mg, under Brand name NEXAVAR, in the US market. For the 12 months ended 31 December 2015, NEXAVAR had US sales of approximately $300 million (as per Bayers annual report).

Natco Pharmas consolidated net profit rose 10.7% to Rs 60.24 crore on 103% growth in net sales to Rs 386.77 crore in Q4 March 2016 over Q4 March 2015.

Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.

Powered by Capital Market - Live News

Punj Lloyd drops 9.38% in two sessions
Jun 03,2016

Meanwhile, the BSE Sensex was up 13.41 points, or 0.05%, to 26,857.36.

On BSE, so far 4.68 lakh shares were traded in the counter, compared with an average volume of 2.35 lakh shares in the past one quarter. The stock hit a low of Rs 18.30 in intraday trade so far, which is record low for the counter. The stock hit a high of Rs 19.30 so far during the day. The stock hit a 52-week high of Rs 35.80 on 6 August 2015.

Punj Lloyd after trading hours on 1 June 2016, said that the High Court of Justice, Queens Bench Division, Commercial Court, UK has ordered the company and its subsidiary, Punj Lloyd Upstream (PLUL), to pay $26.17 million plus summary assessment costs amounting to 75000 pounds, to International Finance Corporation (IFC), towards their claims. The company said it is considering various legal options and shall take appropriate steps in respect of such order. The stock dropped 5.19% to settle at Rs 19.20 yesterday, 2 June 2015 after the announcement. The stock dropped 9.38% in two trading sessions to its current ruling price of Rs 18.35 from the closing price of Rs 20.25 on 1 June 2016.

Punj Lloyd posted net loss of Rs 467.99 crore in Q4 March 2016, compared to net profit of Rs 268.53 crore for Q4 March 2015. The companys net sales decreased 44.9% to Rs 688.13 crore in Q4 March 2016 over Q4 March 2015.

Punj Lloyd is a diversified international conglomerate offering EPC services in energy and infrastructure along with engineering and manufacturing capabilities in the defence sector. Punj Lloyd has operations spread across 24 countries, a mix across the Middle East, Africa, the Caspian, Europe, Asia Pacific and South Asia.

Powered by Capital Market - Live News

Fertilizer stocks gain after IMD retains previous forecast of good rains for 2016 monsoon season
Jun 03,2016

Meanwhile, the S&P BSE Sensex was up 10.69 points or 0.1% at 26,860.32.

Rashtriya Chemicals & Fertilizers (up 1.5%), Gujarat Narmada Valley Fertilizers & Chemicals (up 2.92%), Deepak Fertilisers & Petrochemicals Corporation (up 1.1%), Fertilizers & Chemicals Travancore (up 1.48%), Gujarat State Fertilizers & Chemicals (up 1.73%), Chambal Fertilizers & Chemicals (up 0.37%) and Coromandel International (up 1.94%) rose. National Fertilizers fell 1.35%.

Good rains may boost demand for fertilizers.

Meanwhile, Indias weather office India Meteorological Department (IMD) in its second stage monsoon forecast issued after trading hours yesterday, 2 June 2016, said that rainfall over the country as a whole for the 2016 southwest monsoon season is most likely to be above normal. Quantitatively, monsoon season rainfall for the country as a whole is likely to be 106% of the long period average (LPA) with a model error of plus/minus 4%. In its first stage forecast issued on 12 April 2016, the IMD had forecast rainfall to be 106% of the LPA with a model error of plus/minus 5%.

In its region wise forecast, the IMD said that the rainfall is likely to be 108% of LPA in North-West India, 113% of LPA in Central India, 113% of LPA in South Peninsula and 94% of LPA in North-East India, all with a model error of plus/minus 8%. The rainfall over the country as whole is likely to be 107% of its LPA during July 2016 and 104% of LPA during August 2016 both with a model error of plus/minus 9%. The quantum of the rainfall and its spatial and temporal distribution are critical for the countrys agriculture.

The IMD said that the rapidly declining El Nino conditions became weak in early May 2016 and now have turned to neutral ENSO conditions. Recent changes in the atmospheric conditions over the Pacific also reflect the weakening El Nino conditions. Latest forecast from IMD-IITM coupled model indicates about 50% probability of La Nina conditions to establish during the monsoon season. Most of the other models also suggest development of La Nina conditions during the latter part of the monsoon season. El Nino conditions cause deficient rains in India whereas La Nina conditions trigger abundant rains in the country.

Powered by Capital Market - Live News

Sical Logistics gains after subsidiary receives letter of intent from Kamarajar Port
Jun 03,2016

The announcement was made during market hours today, 3 June 2016.

Meanwhile, the S&P BSE Sensex was down 20.98 points or 0.08% at 26,822.16.

High volumes were witnessed on the counter. On BSE, so far 49,603 shares were traded in the counter as against average daily volume of 6,394 shares in the past one quarter. The stock hit a high of Rs 153.10 and a low of Rs 147.20 so far during the day. The stock had hit a record high of Rs 203.20 on 5 August 2015. The stock had hit a 52-week low of Rs 114 on 12 June 2015. The stock had outperformed the market over the past one month till 2 June 2016, gaining 9.63% compared with Sensexs 5.53% gains. The scrip had, however, underperformed the market in past one quarter, rising 9.06% as against Sensexs 10.73% gains.

The small-cap company has equity capital of Rs 55.60 crore. Face value per share is Rs 10.

Sical Logistics announced that its subsidiary Sical Iron Ore Terminals has been awarded the letter of intent by Kamarajar Port for modification of the existing iron ore terminal on as is where is to also handle common user coal at Kamarajar Port on design, build, finance, operate, and transfer (DBFOT) basis.

Sical Logistics consolidated net profit fell 48.6% to Rs 8.34 crore on 26% growth in net sales to Rs 239.05 crore in Q4 March 2016 over Q4 March 2015.

Sical Logistics is integrated logistics solutions provider with over 5 decades of experience in providing end to end logistics solutions.

Powered by Capital Market - Live News

Airline stocks decline as crude oil prices rise
Jun 03,2016

Meanwhile, the S&P BSE Sensex was up 27.92 points or 0.1% at 26,871.06

SpiceJet (down 4.8%), InterGlobe Aviation (down 1.61%) and Jet Airways (India) (down 1.58%) declined. Higher crude oil prices adversely affect aviation firms as jet fuel prices, which typically constitute about 50% of airlines operating costs, are directly linked to international crude oil prices.

Brent for August settlement was currently up 13 cents at $50.17 a barrel. The contract had risen 32 cents or 0.64% to settle at $50.04 a barrel during the previous trading session after a weekly report showed a decline in US crude inventories.

Powered by Capital Market - Live News

Volumes jump at IIFL Holdings counter
Jun 03,2016

IIFL Holdings clocked volume of 14.53 lakh shares by 13:45 IST on BSE, a 538.36 times surge over two-week average daily volume of 3,000 shares. The stock jumped 9.03% at Rs 227.

Idea Cellular notched up volume of 2.33 crore shares, a 51.43-fold surge over two-week average daily volume of 4.54 lakh shares. The stock slumped 9.93% to Rs 106.60 after reports that a private equity investor has pared its stake in the company through bulk deals today, 3 June 2016. A bulk deal of 76.51 lakh shares was executed on the Idea Cellular scrip at Rs 111.20 per share at the opening bell on BSE today, 3 June 2016. As per reports, private equity investor Providence Equity Partners has offloaded almost half of its holding in Idea Cellular through bulk deals on BSE and NSE today, 3 June 2016. Providence Equity Partners through P5 Asia Investments (Mauritius) owned 6.81% stake in Idea Cellular as on 31 March 2016.

J Kumar Infraprojects saw volume of 2.66 lakh shares, a 25.28-fold surge over two-week average daily volume of 11,000 shares. The stock advanced 0.98% at Rs 243.05.

Gayatri Projects clocked volume of 2.94 lakh shares, a 24.75-fold surge over two-week average daily volume of 12,000 shares. The stock shed 0.46% at Rs 577.50.

Unichem Laboratories saw volume of 3.96 lakh shares, a 20.85-fold rise over two-week average daily volume of 19,000 shares. The stock declined 2.7% at Rs 261.35.

Powered by Capital Market - Live News

MOIL spurts as board to consider share buyback proposal
Jun 03,2016

The announcement was made after market hours yesterday, 2 June 2016.

Meanwhile, the S&P BSE Sensex was up 88.72 points or 0.33% at 26,931.86

On BSE, so far 99,000 shares were traded in the counter as against average daily volume of 21,247 shares in the past one quarter. The stock hit a high of Rs 255 and a low of Rs 232.60 so far during the day. The stock had hit a record low of Rs 180.10 on 12 February 2016. The stock had hit a 52-week high of Rs 257 on 25 June 2015. The stock had hit a 52-week high of Rs 186.50 on 22 July 2015. The stock had underperformed the market over the past one month till 2 June 2016, falling 10.68% compared with Sensexs 5.53% gains. The scrip, however, outperformed the market in past one quarter, rising 13.35% as against Sensexs 10.73% gains.

The mid-cap company has equity capital of Rs 168 crore. Face value per share is Rs 10.

MOILs net profit declined 79.1% to Rs 21.38 crore on 29.9% growth in net sales to Rs 209.62 crore in Q4 March 2016 over Q4 March 2015.

MOIL operates 10 mines, six located in the Nagpur and Bhandara districts of Maharashtra and four in the Balaghat district of Madhya Pradesh. The Government of India (GoI) held 71.57% stake in the company (as per the shareholding pattern as on 31 March 2016).

Powered by Capital Market - Live News

Indiabulls Housing Finance gains after announcing plans to raise funds
Jun 03,2016

The announcement was made after market hours yesterday, 2 June 2016.

Meanwhile, the S&P BSE Sensex was up 68.19 points or 0.29% at 26,911.33.

On BSE, so far 24,074 shares were traded in the counter as against average daily volume of 1.91 lakh shares in the past one quarter. The stock hit a high of Rs 749 and a low of Rs 737.40 so far during the day. The stock had hit a record high of Rs 820 on 10 August 2015. The stock had hit a 52-week low of Rs 542.75 on 3 June 2015. The stock had outperformed the market over the past one month till 2 June 2016, gaining 5.64% compared with Sensexs 5.53% gains. The scrip had also outperformed the market in past one quarter, rising 12.65% as against Sensexs 10.73% gains.

The large-cap company has equity capital of Rs 84.27 crore. Face value per share is Rs 2.

Indiabulls Housing Finance announced that it has proposed to issue 400 secured non-convertible redeemable debentures with a face value of Rs 10 lakh each aggregating to Rs 40 crore with Greenshoe Option on private placement basis.

Indiabulls Housing Finance said that the issue of non-convertible redeemable debentures will open on 7 June 2016 and will also close on the same day. The issue has two options with same coupon rate of 9% per annum payable annually and have tenors of 5 years and ten years.

Indiabulls Housing Finances consolidated net profit rose 22.6% to Rs 675.50 crore on 25% growth in total income to Rs 2647.19 crore in Q4 March 2016 over Q4 March 2015.

Indiabulls Housing Finance is a housing finance company. The company also provides other loans, such as loan against residential properties for home improvement and to small businesses, commercial vehicle loans, and corporate loans for housing projects.

Powered by Capital Market - Live News

Idea Cellular tumbles on huge volumes
Jun 03,2016

Meanwhile, the S&P BSE Sensex was up 55.38 points or 0.21% at 26,898.52

The stock dropped on huge volume. On BSE, so far 2.25 crore shares were traded in the counter as against average daily volume of 7.30 lakh shares in the past one quarter. The stock hit a high of Rs 113.60 and a low of Rs 104.85 so far during the day. The stock had hit a 52-week low of Rs 97.55 on 10 February 2016. The stock had hit a 52-week high of Rs 186.50 on 22 July 2015. The stock had underperformed the market over the past one month till 2 June 2016, rising 0.68% compared with Sensexs 5.53% gains. The scrip, however, outperformed the market in past one quarter, rising 10.92% as against Sensexs 10.73% gains.

The large-cap company has equity capital of Rs 3600.63 crore. Face value per share is Rs 10.

A bulk deal of 76.51 lakh shares was executed on the Idea Cellular scrip at Rs 111.20 per share at the opening bell on BSE today, 3 June 2016. As per reports, private equity investor Providence Equity Partners has offloaded almost half of its holding in Idea Cellular through bulk deals on BSE and NSE today, 3 June 2016. Providence Equity Partners through P5 Asia Investments (Mauritius) owned 6.81% stake in Idea Cellular as on 31 March 2016.

Idea Cellulars consolidated net profit fell 38.9% to Rs 575.63 crore on 10.6% growth in total income to Rs 9524.09 crore in Q4 March 2016 over Q4 March 2015.

Idea Cellular is one of the leading telecom operators in India. It is a part of the Aditya Birla Group.

Powered by Capital Market - Live News

Navkar Corp gains after receipt of contract
Jun 03,2016

The announcement was made after market hours yesterday, 2 June 2016.

Meanwhile, the S&P BSE Sensex was up 74.88 points or 0.28% at 26,918.02

On BSE, so far 24,000 shares were traded in the counter as against average daily volume of 41,293 shares in the past one quarter. The stock had hit a high of Rs 204.05 and low of Rs 197.30 so far during the day. The stock had hit a record high of Rs 221 on 14 February 2015. The stock had hit a 52-week low of Rs 151 on 3 March 2016. The stock had underperformed the market over the past one month till 2 June 2016, rising 4.35% compared with Sensexs 5.53% gains. The scrip, however, outperformed the market in past one quarter, rising 23.45% as against Sensexs 10.73% gains.

The company has equity capital of Rs 142.61 crore. Face value per share is Rs 10.

Navkar Corporation said that the companys wholly-owned subsidiary, Navkar Terminals, received contract for operation and management of Kribhco Infrastructures container freight station (CFS)/ICD and handling of container trains at Hazira Terminal, Gujarat.

On consolidated basis, the companys net profit rose 107.4% to Rs 25.80 crore on 7.8% growth in net sales to Rs 89.70 crore in Q4 March 2016 over Q4 March 2015.

Navkar Corporation is a container freight stations (CFSs) operator in India with three CFSs. The company operates in close proximity to the Jawaharlal Nehru Port (JNP), the largest container port in India. The companys three CFSs and private railway freight terminal (PFT) operations are spread over 3.59 million sq. ft., of which 1.63 million sq. ft. have been notified as a customs area.

Powered by Capital Market - Live News